الفهرس 
General IntroductionOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
Development and Evaluation of Some Nanometric Drug Delivery Systems for Cancer Targeting: This thesis is highlighting focus on two vital drugs in treatment of cancer (Aloe-emodin) and (Rapamycin). In spite of their importance in treatment various types of cancer, they are suffering from obstacles in parenteral delivery. The current thesis investigated relevance of nanomedicine to improve the anti-cancer efficacy of the two drugs via incorporation into liquid crystalline nanoparticles. The work in the current thesis is divided into two parts: Part one Development, In-vitro Cytotoxicity and Pharmacokinetics of PEGylated Monoolein-based Liquid Crystalline Nanoparticles of Aloe-emodin for Cancer Therapy Aloe-emodin (AE) is herbal, anthraquinone drug isolated from either Aloe barbadensis Miller or Rheum palmatum L. with potential anticancer activity against many tumors. However, AE suffers from low oral bioavailability that could be attributed to its poor aqueous solubility, poor intestinal absorption and fast elimination. Therefore, traditional oral administration would not be the suitable method of AE administration. In another avenue, the hydrophobicity of AE and its inherent crystallization tendency in aqueous solution significantly disabled the parenteral administration of AE for chemotherapy. Hence, in this part PEGylated Monoolein-based liquid crystalline nanoparticles of AE were first fabricated for enhanced water solubility and anti-tumor activity. Chapter one: Preparation and In-vitro characterization of PEGylated Monoolein-based Liquid Crystalline Nanoparticles of Aloe-emodin The current work adopted fabrication of PEGylated LCNPs of Aloe-emodin. Two preparation methods were employed in this study including emulsification method and thin film hydration method. The latter method was discouraged due to its failure to efficiently incorporate AE in the lipidic matrix. Fourteen formulations were prepared by emulsification method, the formulations were varied for their stabilizer concentration, AE loading and concentration of the PEGylated phospholipid (m-PEG2KDSPE) that used to induce LCNPs PEGylation. Optimum formulations were selected depending on their quality attributes including PS, PDI, zeta potential and EE%. Further, solidification of prepared AE-LCNPs and PEGylated form was successfully achieved by freeze drying. Complete physicochemical characterization of the formulations was performed including DSC, IR, XRD, TEM and in-vitro release study.